Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors

Ren Yuan Bai, Dominic Esposito, Ada J. Tam, Frank McCormick, Gregory J. Riggins, D. Wade Clapp, Verena Staedtke

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Neurofibromatosis type 1, including the highly aggressive malignant peripheral nerve sheath tumors (MPNSTs), is featured by the loss of functional neurofibromin 1 (NF1) protein resulting from genetic alterations. A major function of NF1 is suppressing Ras activities, which is conveyed by an intrinsic GTPase-activating protein-related domain (GRD). In this study, we explored the feasibility of restoring Ras GTPase via exogenous expression of various GRD constructs, via gene delivery using a panel of adeno-associated virus (AAV) vectors in MPNST and human Schwann cells (HSCs). We demonstrated that several AAV serotypes achieved favorable transduction efficacies in those cells and a membrane-targeting GRD fused with an H-Ras C-terminal motif (C10) dramatically inhibited the Ras pathway and MPNST cells in a NF1-specific manner. Our results opened up a venue of gene replacement therapy in NF1-related tumors.

Original languageEnglish (US)
Pages (from-to)277-286
Number of pages10
JournalGene Therapy
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2019

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors'. Together they form a unique fingerprint.

  • Cite this

    Bai, R. Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019). Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Therapy, 26(6), 277-286. https://doi.org/10.1038/s41434-019-0080-9